Research graph
References from Screening of world approved drugs against highly dynamical spike glycoprotein of SARS-CoV-2 using CaverDock and machine learning. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2020 · External reference
Care for critically ill patients with COVID-19
10.1001/jama.2020.3633 · 2020 · External reference
Shindo and WHO scientific and technical advisory group for infectious hazards, COVID-19: what is next for public health?
10.1016/s0140-6736(20)30374-3 · 2020 · External reference
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — the latest 2019 novel coronavirus outbreak in Wuhan, China
10.1016/j.ijid.2020.01.009 · 2020 · External reference
Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M pro
2020 · External reference
10.1038/s41586-020-2223-y
10.1038/s41586-020-2223-y · External reference
10.1038/news050110-3
10.1038/news050110-3 · External reference
10.1371/journal.pbio.3000815
10.1371/journal.pbio.3000815 · External reference
Coronavirus vaccine development: from SARS and MERS to COVID-19
10.1186/s12929-020-00695-2 · 2020 · External reference
10.1371/journal.pone.0035421
10.1371/journal.pone.0035421 · External reference
10.1073/pnas.0409065102
10.1073/pnas.0409065102 · External reference
COVID-19 VACCINE IS HERE!!!
2020 · External reference
The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine – United States, December 2020
10.15585/mmwr.mm695152e1 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved
2020 · External reference
Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
10.1016/j.compbiolchem.2020.107325 · 2020 · External reference
Combined use of amentoflavone and ledipasvir could interfere with binding of spike glycoprotein of SARS-CoV-2 to ACE2
2020 · External reference
10.1177/0192623320959090
10.1177/0192623320959090 · External reference
COVID-19 vaccine testing in pregnant females is necessary
2020 · External reference
10.7326/m20-6169
10.7326/m20-6169 · External reference
10.1016/j.addr.2020.12.008
10.1016/j.addr.2020.12.008 · External reference
COVID-19 vaccine research and development: ethical issues
10.1111/tmi.13503 · 2021 · External reference
10.1128/jvi.02232-10
10.1128/jvi.02232-10 · External reference
10.1161/hypertensionaha.120.15291
10.1161/hypertensionaha.120.15291 · External reference
10.1101/2020.03.30.015891
10.1101/2020.03.30.015891 · External reference
10.1126/science.abb2507
10.1126/science.abb2507 · External reference
10.1016/j.arcmed.2020.05.012
10.1016/j.arcmed.2020.05.012 · External reference
10.1128/jvi.01052-08
10.1128/jvi.01052-08 · External reference
10.1038/s41467-020-15562-9
10.1038/s41467-020-15562-9 · External reference
10.1002/med.21430
10.1002/med.21430 · External reference
HIV protease inhibitors: a review of molecular selectivity and toxicity
2015 · External reference
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides
10.1073/pnas.0400576101 · 2004 · External reference
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
10.1186/1743-422x-2-69 · 2005 · External reference
10.1080/14728222.2017.1271415
10.1080/14728222.2017.1271415 · External reference
10.1016/j.cell.2020.02.058
10.1016/j.cell.2020.02.058 · External reference
Leucoefdin a potential inhibitor against SARS CoV-2 Mpro
2020 · External reference
Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19
2020 · External reference
10.3390/v12090942
10.3390/v12090942 · External reference
Natural-like products as potential SARS-CoV-2 Mpro inhibitors: in-silico drug discovery
2020 · External reference
Comparative molecular docking analysis of the SARS CoV-2 Spike glycoprotein with the human ACE-2 receptors and thrombin
10.6026/97320630016532 · 2020 · External reference
10.1016/j.compbiomed.2020.103936
10.1016/j.compbiomed.2020.103936 · External reference
10.1016/j.antiviral.2020.104873
10.1016/j.antiviral.2020.104873 · External reference
Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in-silico study for drug development
2020 · External reference
Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach
2020 · External reference
10.1016/j.virusres.2020.198068
10.1016/j.virusres.2020.198068 · External reference
Alchemical free energy methods for drug discovery: progress and challenges
10.1016/j.sbi.2011.01.011 · 2011 · External reference
Robust free energy perturbation protocols for creating molecules in solution
10.1021/acs.jctc.9b00213 · 2019 · External reference
Ligand migration in the truncated hemoglobin-II from Mycobacterium tuberculosis THE ROLE OF G8 TRYPTOPHAN
10.1074/jbc.m806183200 · 2009 · External reference
An atomistic view on human hemoglobin carbon monoxide migration processes
10.1016/j.bpj.2012.01.011 · 2012 · External reference
Fast screening of inhibitor binding/unbinding using novel software tool CaverDock
2019 · External reference
CaverDock: a novel method for the fast analysis of ligand transport
2019 · External reference
10.1093/bioinformatics/btz386
10.1093/bioinformatics/btz386 · External reference
3.0: a tool for the analysis of transport pathways in dynamic protein structures
10.1371/journal.pcbi.1002708 · 2012 · External reference
10.1002/jcc.21334
10.1002/jcc.21334 · External reference
10.1093/nar/gkz378
10.1093/nar/gkz378 · External reference
Caver web: identification of tunnels and channels in proteins and analysis of ligand transport
10.1016/j.jbiotec.2019.05.251 · 2019 · External reference
Unresolved reference
External reference
10.1093/nar/28.1.235
10.1093/nar/28.1.235 · External reference
10.1021/acs.jcim.5b00559
10.1021/acs.jcim.5b00559 · External reference
Enhanced sampling in molecular dynamics
10.1063/1.5109531 · 2019 · External reference
10.1021/ct9000685
10.1021/ct9000685 · External reference
10.1002/jcc.540130812
10.1002/jcc.540130812 · External reference
10.1073/pnas.202427399
10.1073/pnas.202427399 · External reference
10.1016/s0009-2614(99)01123-9
10.1016/s0009-2614(99)01123-9 · External reference
10.1063/1.1755656
10.1063/1.1755656 · External reference
10.1016/j.cplett.2006.05.062
10.1016/j.cplett.2006.05.062 · External reference
Efficient, multiple-range random walk algorithm to calculate the density of states
10.1103/physrevlett.86.2050 · 2001 · External reference
10.1093/nar/gks1200
10.1093/nar/gks1200 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1016/s0263-7855(97)00009-x
10.1016/s0263-7855(97)00009-x · External reference
10.1186/s13321-018-0258-y
10.1186/s13321-018-0258-y · External reference
10.1002/jcc.21256
10.1002/jcc.21256 · External reference
PLS regression methods
10.1002/cem.1180020306 · 1988 · External reference
Unresolved reference
External reference
Multivariate quantitative structure-activity relationships (QSAR): conditions for their applicability
10.1021/ci00037a002 · 1983 · External reference
Validation of QSAR’s
10.1002/qsar.19910100302 · 1991 · External reference
10.1021/ct300418h
10.1021/ct300418h · External reference
Unresolved reference
2015 · External reference
Unresolved reference
External reference
10.1021/acs.jctc.5b00255
10.1021/acs.jctc.5b00255 · External reference
10.1021/ct200909j
10.1021/ct200909j · External reference
Speed without compromise – a mixed precision model for GPU accelerated molecular dynamics simulations
10.1016/j.cpc.2012.09.022 · 2013 · External reference
Unresolved reference
2016 · External reference
10.1002/(sici)1096-987x(19990130)20:2<217::aid-jcc4>3.0.co;2-a
10.1002/(sici)1096-987x(19990130)20:2<217::aid-jcc4>3.0.co;2-a · External reference
10.1093/nar/gkj067
10.1093/nar/gkj067 · External reference
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
10.1038/s41598-020-70863-9 · 2020 · External reference
10.1126/sciadv.abb8097
10.1126/sciadv.abb8097 · External reference
10.3390/jcm9051473
10.3390/jcm9051473 · External reference
10.1007/s11655-020-3427-6
10.1007/s11655-020-3427-6 · External reference
High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein
2020 · External reference
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
2020 · External reference
